Dermatitis
Drug research and approvals for dermatitis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 17, 2026, 234 studies of dermatitis are recruiting on ClinicalTrials.gov, Health Canada has authorized 213 drug trials for it since 2013, FDA has 0 approved and 2 open orphan designations naming it, and the EU has 8 authorised medicines for it.
- Recruiting worldwide: 234
- Trials authorized in Canada: 213
- FDA orphan approvals: 0
- EU medicines: 8
Recruiting Now
Newest start dates first, of 234 recruiting on ClinicalTrials.gov ↗- Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or…NCT07262983 · Phase 1 · National Institute of Allergy and Infectious Diseases (NIAID) · starts Nov 19, 2026
- Digital Mindfulness Meditation in Adolescents With Atopic DermatitisNCT07746427 · Not applicable · Weill Medical College of Cornell University · starts Nov 15, 2026
- Thalidomide for Preventing Radiation-Induced Dermatitis in Breast Cancer PatientsNCT07933653 · Not applicable · First Affiliated Hospital of Guangxi Medical University · starts Nov 12, 2026
- A Study of Different Skin Care Approaches to Prevent Skin Reactions in People With Breast Cancer Receiving Radiation…NCT07918989 · Phase 2 · Memorial Sloan Kettering Cancer Center · starts Oct 30, 2026
- Roflumilast Cream 0.3% for Moderate to Severe Atopic DermatitisNCT07916480 · Phase 3 · Arcutis Biotherapeutics, Inc. · starts Oct 30, 2026
- A Study for AR100DP1 in Mild to Moderate Atopic DermatitisNCT07914088 · Phase 2 · Arjil Pharmaceuticals LLC · starts Oct 21, 2026
- Observational Analytical Validation Study of the Replior ScratchSenseNCT07909967 · Not reported · Replior AB · starts Oct 12, 2026
- Randomized, Double-blind, Placebo-controlled Study of Nemolizumab in Chinese Subjects With Moderate-to-severe Atopic…NCT07762833 · Phase 3 · Galderma R&D · starts Oct 8, 2026
- In Vitro Susceptibility of Dermatophytes to Terbinafine and Itraconazole: MIC Distributions and Elevated-MIC Isolates…NCT07898475 · Not reported · Dr. Amara Safdar · starts Oct 2, 2026
- Phase II Clinical Study to Evaluate the Efficacy and Safety of LT-002-158 Tablets in Adult Patients With…NCT07895615 · Phase 2 · Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. · starts Oct 1, 2026
Drug Pipeline
9 approved, 10 in phase 3, 11 in phase 2, 12 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this conditionApproved: Dexamethasone, Gentamicin, Zinc oxide, Betamethasone acetate, Triamcinolone acetonide, Methylprednisolone hemisuccinate, Methylprednisolone acetate, Dimethicone, Aluminum chlorohydrate
- Dupilumab
- Phase 3 Interleukin-4 receptor subunit alpha antagonist
- Cetirizine
- Phase 3 Histamine H1 receptor antagonist
- Levocetirizine
- Phase 3 Histamine H1 receptor antagonist
- Butenafine
- Phase 3 Squalene monooxygenase inhibitor
- Ketoconazole
- Phase 3 Cytochrome P450 51 inhibitor
- Pimecrolimus
- Phase 3 FK506-binding protein 1A inhibitor
- Clemastine
- Phase 3 Histamine H1 receptor antagonist
- Desloratadine
- Phase 3 Histamine H1 receptor antagonist
- Bepotastine
- Phase 3 Histamine H1 receptor antagonist
- Ketotifen
- Phase 3 Histamine H1 receptor antagonist
- Acitretin
- Phase 2 Retinoid receptor agonist
- Doxycycline anhydrous
- Phase 2 Matrix metalloproteinase 7 inhibitor
- Roflumilast
- Phase 2 Phosphodiesterase 4 inhibitor
- Sulfamethoxazole
- Phase 2 Bacterial dihydropteroate synthase inhibitor
- Trimethoprim
- Phase 2 Bacterial dihydrofolate reductase inhibitor
- Cephalexin anhydrous
- Phase 2 Bacterial penicillin-binding protein inhibitor
- Apremilast
- Phase 2 Phosphodiesterase 4 inhibitor
- Crisaborole
- Phase 2 Phosphodiesterase 4 inhibitor
- Risankizumab
- Phase 2 Interleukin-23 inhibitor
- Gusacitinib
- Phase 2 Janus Kinase (JAK) inhibitor
- Hypochlorous acid
- Phase 2
- Ruxolitinib
- Phase 1 Tyrosine-protein kinase JAK1 inhibitor
- Olive oil
- Phase 1
- Adriforant
- Phase 1 Histamine H4 receptor antagonist
- Etokimab
- Phase 1 Interleukin-33 binding agent
- Udifitimod
- Phase 1
- Tozorakimab
- Phase 1
- Temtokibart
- Phase 1
- Idrebormilast
- Phase 1
- Ompekimig
- Phase 1
Showing the 30 furthest along of 33 in trials.
How Its Trials Ended
1,674 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 372 whose ending is known, 48% met their primary endpoint, 4% missed it and 48% stopped early.
- Completed, result not reported81449%
- Ongoing33520%
- Met its primary endpoint17911%
- Status unknown1539%
- Stopped: other or unclear905%
- Stopped: lack of efficacy292%
- Stopped: enrollment or feasibility292%
- Stopped: sponsor or business decision221%
- Missed its primary endpoint141%
- Stopped: funding91%
Trials Authorized in Canada
The 10 newest of 213; search them all in Canada trials| Sep 16, 2026 | A phase 3, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of rezpegaldesleukin (nktr-358) monotherapy…Rezpegaldesleukin (NKTR-358) | Nektar Therapeutics | Pending |
| Sep 10, 2026 | A randomized, double-blind, parallel group, placebo-controlled phase 3 combination therapy study to investigate the efficacy & safety oftilrekimig in adult &…Tilrekimig (PF-07275315) | Pfizer | Ongoing |
| Sep 2, 2026 | A phase 3, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of rezpegaldesleukin (nktr-358) monotherapy…Rezpegaldesleukin (NKTR-358) | Nektar Therapeutics | Ongoing |
| Sep 2, 2026 | A phase 3, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of rezpegaldesleukin (nktr-358) monotherapy…Rezpegaldesleukin (NKTR-358) | Nektar Therapeutics | Ongoing |
| Aug 12, 2026 | A phase 2, randomized, multicenter, double-blind, placebo-controlled study to evaluate the efficacy, safety, and pharmacokinetics of multiple subcutaneous…TRIV-573 | Triveni Bio, Inc. | Pending |
| Jun 18, 2026 | A phase 2 multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and preliminary efficacy of soquelitinib in…Soquelitinib (CPI-818) | Corvus Pharmaceuticals Inc | Ongoing |
| Jun 8, 2026 | A phase 2b, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study to evaluate the efficacy and safety of env-294 in adult…ENV-294 | Enveda Therapeutics Inc | Pending |
| Jun 4, 2026 | A long-term extension study to evaluate the safety and efficacy of subcutaneous img-007 in participants of a previous img-007 moderate-to-severe atopic…IMG-007 | Inmagene LLC | Ongoing |
| Apr 9, 2026 | A phase 2b, multicenter, randomized, doubleblind, placebo-controlled study to evaluate the efficacy and safety of camoteskimab in adults with…Camoteskimab (APL-9109) | Apollo Therapeutics, Limited | Ongoing |
| Dec 30, 2025 | A pilot study designed to evaluate the use of pch-415 in aiding in the diagnosis of allergic contact dermatitisPCH-415 diagnostic patch (pre-filled diagnostic patch test system) | Evme, Inc. | Ongoing |
FDA Orphan Designations
Approved first, then open designations, newest first| Oct 24, 1991 | MetronidazoleTreatment of perioral dermatitis. | Galderma Laboratories, Inc. | Designated |
| Sep 10, 1990 | SulfapyridineTreatment of dermatitis herpetiformis. | Jacobus Pharmaceutical Company | Designated |
Medicines Authorised in the EU
Newest first| Feb 12, 2025 | NemluvioNemolizumab | Galderma International | EMA ↗ |
| Sep 19, 2024 | AnzupgoDelgocitinib | LEO Pharma A/S | EMA ↗ |
| Nov 16, 2023 | EbglyssLebrikizumab | Almirall, S.A. | EMA ↗ |
| Apr 19, 2023 | OpzeluraRuxolitinib | Incyte Biosciences Distribution B.V. | EMA ↗ |
| Dec 9, 2021 | CibinqoAbrocitinib | Pfizer Europe MA EEIG | EMA ↗ |
| Jun 17, 2021 | AdtralzaTralokinumab | LEO Pharma A/S | EMA ↗ |
| Sep 26, 2017 | DupixentDupilumab | Sanofi Winthrop Industrie | EMA ↗ |
| Feb 27, 2002 | ProtopicTacrolimus | LEO Pharma A/S | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA